Blackbird Labs

Executive Summary

Blackbird Labs is a preclinical biotechnology company pioneering metabolic and regenerative medicine approaches to combat age-related diseases. Founded in 2020 and based in San Francisco, the company targets fundamental metabolic pathways to restore tissue health and function, with a pipeline spanning cellular rejuvenation and systemic metabolic modulation. Having raised $100M in venture funding, Blackbird is well-capitalized to advance its lead programs toward the clinic. The company's interdisciplinary platform integrates insights from aging biology, metabolism, and regenerative medicine, positioning it to address major unmet needs in diseases such as sarcopenia, metabolic dysfunction, and tissue degeneration. Blackbird's early-stage research has generated promising preclinical data highlighting the therapeutic potential of its metabolic interventions. The company is now focused on selecting lead candidates for IND-enabling studies and is actively engaging with academic and industry partners to accelerate development. With a strong scientific foundation and substantial financial backing, Blackbird is poised to transition from discovery to development over the next 12–18 months. Key upcoming milestones include the completion of key efficacy studies, potential Series B financing to fund clinical trials, and strategic collaborations with pharmaceutical partners in the aging and metabolic space.

Upcoming Catalysts (preview)

• Q4 2026Lead program IND filing70% success
• Q1 2027Series B financing round80% success
• Q3 2026Strategic partnership with major pharma60% success